title: [Raltegravir in HIV-infected patients with high vascular risk].
abstract: OBJECTIVE
  To record the experience with use of raltegravir (RTG) for devising highly active antiretroviral therapy (HAART) regimens based on RTG in high vascular risk patients.
  
  
  METHODS
  A retrospective study was conducted on high vascular risk patients taking RTG. Case was a patient who, at the time raltegravir was started, had ≥ 20% 10-year risk of cardiovascular disease, estimated by the algorithm of the European AIDS Clinical Society. Patients should have been on stable HAART including RTG for at least six months. A matched control with ≥ 20% risk of cardiovascular disease, was selected for each case.
  
  
  RESULTS
  Ten controls and ten cases were selected. After six months using RTG, a significant decreased was seen in levels of HDL cholesterol (median -2,5mg/dL in controls versus 2,5mg/dL in cases, p=0.015), triglycerides (10mg/dL versus -101 mg/dL, p=0.009), and TC/HDL-C ratio (0.17 versus -0.73, p=0.002). Ten-year risk of cardiovascular disease was -4.85% in cases versus -0.05% in controls (p=0.07).
  
  
  CONCLUSIONS
  RTG shows a good profile to be used in people with high vascular risk, with a decrease in TC/HDL-C ratio and vascular risk.
authors.affiliation: Unidad de Medicina Interna, Hospital Costa del Sol, Marbella, Málaga, España. julio.olalla@gmail.com
authors.forename: Julián
authors.initials: J
authors.lastname: Olalla
authors.forename: Alfonso
authors.initials: A
authors.lastname: Del Arco
authors.forename: Javier
authors.initials: J
authors.lastname: de la Torre
authors.forename: Daniel
authors.initials: D
authors.lastname: Salas
authors.forename: José Luis
authors.initials: JL
authors.lastname: Prada
authors.forename: Javier
authors.initials: J
authors.lastname: García-Alegría
mesh_terms: D000368:Aged; D023241:Antiretroviral Therapy, Highly Active; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D016022:Case-Control Studies; D008076:Cholesterol, HDL / Q000097:blood; D015658:HIV Infections / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D011760:Pyrrolidinones / Q000627:therapeutic use*; D000068898:Raltegravir Potassium; D012189:Retrospective Studies; D012306:Risk; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D019428:HIV Integrase Inhibitors; D011760:Pyrrolidinones; D014280:Triglycerides; D000068898:Raltegravir Potassium